method for identifying a subject at risk for or having a pkal-mediated disorder, method for evaluating a treatment of a pkal-mediated disorder in a subject, method for treating a pkal-mediated disease, pharmaceutical composition for use in treating a mediated disease pkal of a subject and method for determining a value of cleaved kininogen, intact kininogen, or both, in a sample

摘要

method for identifying a subject at risk for or having a pkal-mediated disorder, method for determining whether a disorder is susceptible to treatment with a pkal inhibitor, method for assessing treatment of a pkal-mediated disorder in a subject, method for treating a pkal-mediated disease, pharmaceutical composition for use in treating a pkal-mediated disease of a subject, and method for determining a value of cleaved kininogen, intact kininogen, or both, in a sample the present disclosure provides methods for evaluating a subject, for example. for example, a subject at risk for or suffering from a pkal-mediated or bradykinin-mediated disorder based on the values (for example, percentages) of intact and / or cleaved kininogen in a sample of the subject. Provided methods allow analysis of patients with plasma kallikrein-mediated angioedema (kma) or other pkal-mediated diseases useful in the evaluation and treatment. Such methods may involve the use of a detection agent that preferably binds cleaved kininogen or intact kininogen.